Immunotherapy regimens share similar categories of adverse events but differ significantly in frequency and severity.
Of Interest
Tolerability and Patient Factors Influence Use of Dual IO in Melanoma
Immunotherapy (IO) options can induce durable responses in patients with BRAF-negative metastatic melanoma.
Lifileucel Sustains Long-Term Responses and Survival in Advanced Melanoma
Lifileucel therapy achieved a 31.4% objective response rate in advanced melanoma patients, with 5.9% complete responses and 25.5% partial responses.
Engineered viruses and gene therapy halt tumor growth and extend survival in mice
Melanoma is among the most aggressive and common cancers. Surgery, chemotherapy, and radiation therapy have been the mainstay of melanoma treatment, but they fail to control aggressive tumors, especially when resistance develops.